A Double-Blind, Randomized, Crossover Study to Compare the Effectiveness of Montelukast on Atopic Dermatitis in Korean Children
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Joon, You Hoon | - |
dc.contributor.author | Min, Taek Ki | - |
dc.contributor.author | Yang, Hyeon-Jong | - |
dc.contributor.author | Pyun, Bok Yang | - |
dc.date.accessioned | 2021-08-11T17:25:47Z | - |
dc.date.available | 2021-08-11T17:25:47Z | - |
dc.date.issued | 2016-07 | - |
dc.identifier.issn | 2092-7355 | - |
dc.identifier.issn | 2092-7363 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8985 | - |
dc.description.abstract | Purpose: Some studies report a role of leukotrienes in the pathogenesis of atopic dermatitis and suggest a rationale for the use of leukotriene receptor antagonist (LTRA) in the treatment of atopic dermatitis. This study aimed to evaluate the treatment effectiveness of montelukast in children with atopic dermatitis. Methods: Fifty-four children between the ages of 2 and 6 years with moderate to severe atopic dermatitis were enrolled. Group A received montelukast for 8 weeks, followed by a crossover to 8 weeks of placebo after a 2-week washout period. Group B reversed the administration according to a randomized, double-blind, placebo-controlled, crossover design. The SCORing atopic dermatitis (SCORAD) index, urinary leukotriene E-4 (LTE4), and eosinophil-derived neurotoxin (EDN) were assessed at every visit. Results: Forty-three patients (21 males) completed the study. Although the SCORAD index was decreased in both groups, there was no statistically significant difference between montelukast and placebo (-3.0+/-11.2 vs -5.7+/-11.3, P=0.43). The level of urinary LTE4 was decreased after taking montelukast when compared to placebo, but there was no statistically significant difference (-65.9+/-556.2 vs 87.7+/-618.3, P=0.26). The changes in urinary EDN after taking montelukast and placebo had no significant difference (37.0+/-1,008.6 vs -195.8+/-916.7, P=0.10). When analyzing SCORAD indices, urinary LTE4, and EDN, we could not prove the effectiveness of montelukast in the atopic, non-atopic or high ECP (ECP >= 15 mu g/L) subgroups. Conclusions: There was no statistically significant difference in clinical improvement or biomarkers between montelukast and placebo treatment. Therefore, conventional treatments with skin care and infection control might be more important strategies in the treatment of atopic dermatitis. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한천식알레르기학회 | - |
dc.title | A Double-Blind, Randomized, Crossover Study to Compare the Effectiveness of Montelukast on Atopic Dermatitis in Korean Children | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4168/aair.2016.8.4.305 | - |
dc.identifier.scopusid | 2-s2.0-84977551955 | - |
dc.identifier.wosid | 000378972300004 | - |
dc.identifier.bibliographicCitation | Allergy, Asthma & Immunology Research, v.8, no.4, pp 305 - 311 | - |
dc.citation.title | Allergy, Asthma & Immunology Research | - |
dc.citation.volume | 8 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 305 | - |
dc.citation.endPage | 311 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002122372 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Allergy | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Allergy | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | EOSINOPHIL PROTEIN-X | - |
dc.subject.keywordPlus | ECZEMA/DERMATITIS SYNDROME | - |
dc.subject.keywordPlus | DISEASE SEVERITY | - |
dc.subject.keywordPlus | LEUKOTRIENE E-4 | - |
dc.subject.keywordPlus | EXCRETION | - |
dc.subject.keywordPlus | MODERATE | - |
dc.subject.keywordPlus | ECZEMA | - |
dc.subject.keywordPlus | ASTHMA | - |
dc.subject.keywordAuthor | Atopic dermatitis | - |
dc.subject.keywordAuthor | montelukast | - |
dc.subject.keywordAuthor | treatment effectiveness | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.